PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

BMS’ Opdivo plus Yervoy misses the mark in high-risk melanoma

Bristol Myers Squibb has revealed some underwhelming results for its immunotherapy combination treatment Opdivo plus Yervoy in resected high-risk melanoma patients.

In the phase III CheckMate-915 study, PD-1 inhibitor Opdivo (nivolumab) plus CTLA-4 targeting Yervoy (ipilimumab) did not result in a statistically significant improvement in recurrence-free survival in the all-comer population, comprised of patients who have had a complete surgical removal of stage IIIb/c/d or stage IV melanoma.

Back in November 2019, BMS announced that a statistically significant benefit was not reached for the co-primary endpoint of recurrence-free survival in patients whose tumours expressed PD-L1 <1%.

Following these results, BMS plans to complete a full evaluation of the CheckMate-915 data and work with investigators to share the results at an upcoming medical conference.

“We are proud of our legacy in melanoma with both Opdivo and Yervoy. They have each brought significant benefit as monotherapies for appropriate melanoma patients in the adjuvant setting, and as a dual immunotherapy regimen in the metastatic setting,” said Sabine Maier, vice president, Head of Oncology Clinical Development, BMS.

“We remain committed to continued research in melanoma, both to further understand the potential benefit of Yervoy in combination with Opdivo to treat high-risk melanoma patients in the earlier stages of disease, as well as to study additional novel combinations in various settings,” she added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026